ArticleFrontiers in medicine2026
Clinical characteristics and prognostic differences between elderly-onset and adult-onset ulcerative colitis: a two-center retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of elderly-onset ulcerative colitis (EO-UC) has been gradually increasing. The unique characteristics of clinical manifestations, therapeutic strategies, and prognosis in EO-UC patients compared with adult-onset ulcerative colitis (AO-UC) patients remain unclear. Methods: We retrospectively analyzed hospitalized ulcerative colitis (UC) patients from March 2010 to June 2024 at Peking University Third Hospital and Peking University International Hospital. We recruited 68 EO-UC patients (age at diagnosis≥60 years) and 136 AO-UC patients (age at diagnosis <60 years, matched ratio = 1:2). Follow-up lasted from the date of UC diagnosis to the earlier of two endpoints: January 31, 2025, or the date of the last clinical visit at our center. Subsequently, we analyzed the differences in clinical manifestations, therapeutic strategies, and prognosis between the two groups. Results: The male-to-female ratio in the EO-UC group was 1.8:1, and this group had milder clinical manifestations (abdominal pain 58.5% Conclusion: The EO-UC group was predominantly male, and it exhibited higher comorbidity and concomitant medication rates and milder clinical manifestations than the AO-UC group, presenting challenges for clinical diagnosis. 5-Aminosalicylic acid (5-ASA) remains the first-line therapeutic regimen, and the EO-UC group demonstrated lower utilization rates of immunosuppressants and biologics than the AO-UC group, which may be related to distinct treatment considerations in elderly patients, although this did not translate into observable differences in clinical outcomes between the two groups. This study is preliminary and exploratory, and larger prospective studies with adequate sample sizes are needed to validate these findings in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.